Sign In
Buy TBPH
$16.97
+0.410 (+2.48%)
At Close: Jun 23, 2026
Theravance Biopharma Earnings Calls
Mar 31, 2026
-$0.0962 (-443.57%)
| Release date | May 07, 2026 |
| EPS estimate | $0.0280 |
| EPS actual | -$0.0962 |
| EPS Surprise | -443.57% |
| Revenue estimate | 17.783M |
| Revenue actual | 17.699M |
| Revenue Surprise | -0.474% |
Dec 31, 2025
$0.0600 (-86.36%)
| Release date | Mar 19, 2026 |
| EPS estimate | $0.440 |
| EPS actual | $0.0600 |
| EPS Surprise | -86.36% |
| Revenue estimate | 56.589M |
| Revenue actual | 45.891M |
| Revenue Surprise | -18.90% |
Sep 30, 2025
$0.0400 (233.33%)
| Release date | Nov 10, 2025 |
| EPS estimate | -$0.0300 |
| EPS actual | $0.0400 |
| EPS Surprise | 233.33% |
| Revenue estimate | 43.087M |
| Revenue actual | 19.99M |
| Revenue Surprise | -53.61% |
Jun 30, 2025
-$0.0800 (42.86%)
| Release date | Aug 12, 2025 |
| EPS estimate | -$0.140 |
| EPS actual | -$0.0800 |
| EPS Surprise | 42.86% |
| Revenue estimate | 18.728M |
| Revenue actual | 26.195M |
| Revenue Surprise | 39.87% |
Last 4 Quarters for Theravance Biopharma
Below you can see how TBPH performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
Jun 30, 2025
Beat
| Release date | Aug 12, 2025 |
| Price on release | $11.92 |
| EPS estimate | -$0.140 |
| EPS actual | -$0.0800 |
| EPS surprise | 42.86% |
| Date | Price |
|---|---|
| Aug 06, 2025 | $11.18 |
| Aug 07, 2025 | $11.21 |
| Aug 08, 2025 | $11.52 |
| Aug 11, 2025 | $11.40 |
| Aug 12, 2025 | $11.92 |
| Aug 13, 2025 | $12.42 |
| Aug 14, 2025 | $12.94 |
| Aug 15, 2025 | $13.15 |
| Aug 18, 2025 | $13.61 |
| 4 days before | 6.62% |
| 4 days after | 14.18% |
| On release day | 4.19% |
| Change in period | 21.74% |
Sep 30, 2025
Beat
| Release date | Nov 10, 2025 |
| Price on release | $15.08 |
| EPS estimate | -$0.0300 |
| EPS actual | $0.0400 |
| EPS surprise | 233.33% |
| Date | Price |
|---|---|
| Nov 04, 2025 | $14.75 |
| Nov 05, 2025 | $14.95 |
| Nov 06, 2025 | $14.87 |
| Nov 07, 2025 | $14.75 |
| Nov 10, 2025 | $15.08 |
| Nov 11, 2025 | $18.50 |
| Nov 12, 2025 | $17.78 |
| Nov 13, 2025 | $17.95 |
| Nov 14, 2025 | $17.39 |
| 4 days before | 2.24% |
| 4 days after | 15.32% |
| On release day | 22.68% |
| Change in period | 17.90% |
Dec 31, 2025
Missed
| Release date | Mar 19, 2026 |
| Price on release | $14.01 |
| EPS estimate | $0.440 |
| EPS actual | $0.0600 |
| EPS surprise | -86.36% |
| Date | Price |
|---|---|
| Mar 13, 2026 | $13.78 |
| Mar 16, 2026 | $13.93 |
| Mar 17, 2026 | $13.92 |
| Mar 18, 2026 | $13.83 |
| Mar 19, 2026 | $14.01 |
| Mar 20, 2026 | $14.33 |
| Mar 23, 2026 | $14.75 |
| Mar 24, 2026 | $14.90 |
| Mar 25, 2026 | $15.29 |
| 4 days before | 1.67% |
| 4 days after | 9.14% |
| On release day | 2.28% |
| Change in period | 10.96% |
Mar 31, 2026
Missed
| Release date | May 07, 2026 |
| Price on release | $17.02 |
| EPS estimate | $0.0280 |
| EPS actual | -$0.0962 |
| EPS surprise | -443.57% |
| Date | Price |
|---|---|
| May 01, 2026 | $16.79 |
| May 04, 2026 | $16.91 |
| May 05, 2026 | $16.73 |
| May 06, 2026 | $16.94 |
| May 07, 2026 | $17.02 |
| May 08, 2026 | $17.01 |
| May 11, 2026 | $16.52 |
| May 12, 2026 | $16.48 |
| May 13, 2026 | $16.67 |
| 4 days before | 1.37% |
| 4 days after | -2.06% |
| On release day | -0.0588% |
| Change in period | -0.715% |
Theravance Biopharma Earnings History
Earnings Calendar
FAQ
When is the earnings report for TBPH?
Theravance Biopharma (TBPH) has scheduled its earnings report for Aug 11, 2026 before the markets open.
What is the TBPH price-to-earnings (P/E) ratio?
TBPH P/E ratio as of Jun 23, 2026 (TTM) is 7.50.
What is the TBPH EPS forecast?
The forecasted EPS (Earnings Per Share) for Theravance Biopharma (TBPH) for the first fiscal quarter 2026 is $0.0600.
What are Theravance Biopharma's retained earnings?
On its balance sheet, Theravance Biopharma reported retained earnings of $17.70 million for the latest quarter ending Mar 31, 2026.
What Is an Earnings Report?
An earnings report is usually issued quarterly (Q1, Q2, Q3 & Q4) by public companies to report their performance. Earnings reports typically include net income, earnings per share, earnings from continuing operations, and net sales. Looking at the earnings report investors can start gauge the financial health of the company and make even better decisions whether to buy, sell, or stay in the company. Fundamental analysts and value investors will typically hunt for stocks that continue to show good financial ratios and use a decline as an exit point. One of the most anticipated numbers for analysis is earnings per share because it indicates how much the company earned for its shareholders. The report will also indicate a possible dividend.
Earnings Report Content
Earnings reports generally provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. These figures are typically measured against previous quarters/years. Furthermore, the earnings report usually includes a summary and analysis from the CEO or company spokesman, alongside a more general view of the financials and future forecast.
What To Know About Earnings Reports?
Announcement of earnings for a stock, particularly for well followed large-capitalization stocks, can move the market. Stock prices can fluctuate wildly on days when the quarterly earnings report is released. Despite good reports, stocks may very well fall if the investors were expecting more or they believe the next quarter will not be as good. Investors always try to be ahead of the market and future earnings/losses are often discounted into the current price of the stock. It is natural for stocks to start to move in either direction a few days before the release of an earnings report.
